AI assistant
PTC THERAPEUTICS, INC. — Director's Dealing 2020
Oct 9, 2020
31046_dirs_2020-10-09_926d23c3-4be6-488a-9c6a-f741ac6a47cc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PTC THERAPEUTICS, INC. (PTCT)
CIK: 0001070081
Period of Report: 2020-10-07
Reporting Person: Peltz Stuart Walter (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-10-07 | Common Stock | M | 22929 | $10.85 | Acquired | 79014 | Direct |
| 2020-10-07 | Common Stock | S | 11143 | $53.012 | Disposed | 67871 | Direct |
| 2020-10-07 | Common Stock | S | 11786 | $53.692 | Disposed | 56085 | Direct |
| 2020-10-07 | Common Stock | M | 48175 | $11.23 | Acquired | 104260 | Direct |
| 2020-10-07 | Common Stock | S | 16494 | $52.936 | Disposed | 87766 | Direct |
| 2020-10-07 | Common Stock | S | 31681 | $53.616 | Disposed | 56085 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-10-07 | Stock Option (Right to Buy) | $10.85 | M | 22929 | Disposed | 2023-05-15 | Common Stock (22929) | Direct |
| 2020-10-07 | Stock Option (Right To Buy) | $11.23 | M | 48175 | Disposed | 2027-01-02 | Common Stock (48175) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right To Buy) | $490.8 | 2021-04-27 | Common Stock (541.0) | 541 | Direct |
| Stock Option (Right To Buy) | $218.4 | 2022-01-10 | Common Stock (416.0) | 416 | Direct |
| Stock Option (Right to Buy) | $10.85 | 2023-05-15 | Common Stock (52115) | 52115 | Direct |
| Stock Option (Right To Buy) | $27.05 | 2024-01-27 | Common Stock (200000.0) | 200000 | Direct |
| Stock Option (Right To Buy) | $51.0 | 2025-01-01 | Common Stock (300000.0) | 300000 | Direct |
| Stock Option (Right To Buy) | $30.86 | 2026-01-03 | Common Stock (175000.0) | 175000 | Direct |
| Stock Option (Right To Buy) | $18.01 | 2028-01-02 | Common Stock (200000.0) | 200000 | Direct |
| Stock Option (Right To Buy) | $33.02 | 2029-01-21 | Common Stock (265000.0) | 265000 | Direct |
| Stock Option (Right To Buy) | $33.02 | 2029-01-21 | Common Stock (55000.0) | 55000 | Direct |
| Stock Option (Right To Buy) | $51.16 | 2030-01-28 | Common Stock (192500.0) | 192500 | Direct |
Footnotes
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 11, 2020.
F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.40 to $53.39 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.40 to $54.05 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 3, 2020.
F5: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.19 to $53.18 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F6: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.19 to $54.09 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F7: Currently exercisable.
F8: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
F9: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
F10: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
F11: This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
F12: This option was granted on January 29, 2020 and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 29, 2021.